UK markets open in 1 hour 14 minutes
NIKKEI 225
38,626.39 -320.54 (-0.82%) HANG SENG
19,251.51 +30.89 (+0.16%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,417.40 -8.50 (-0.35%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,956.95 -917.55 (-1.64%)
Amgen Inc (AMG.BE)
Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
At close: 08:08AM CEST
| Previous close | 286.80 |
| Open | 288.85 |
| Bid | 289.60 x 0 |
| Ask | 290.45 x 0 |
| Day's range | 288.85 - 288.85 |
| 52-week range | 198.80 - 299.20 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Benzinga
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
- Zacks
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
- Zacks
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
© 2024 Yahoo. All rights reserved.